Last reviewed · How we verify

Relafen — Competitive Intelligence Brief

Relafen (NABUMETONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Anti-inflammatory Drug [EPC]. Area: Immunology.

marketed Nonsteroidal Anti-inflammatory Drug [EPC] Prostaglandin G/H synthase 1 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Relafen (NABUMETONE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Relafen TARGET NABUMETONE marketed Nonsteroidal Anti-inflammatory Drug [EPC] Prostaglandin G/H synthase 1 1991-01-01
Joicela LUMIRACOXIB Novartis Pharmaceuticals UK Limited marketed lumiracoxib Prostaglandin G/H synthase 1 2005-01-01
Etocox ETORICOXIB marketed etoricoxib Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1 2002-01-01
Colazal BALSALAZIDE Valeant Pharms Intl marketed Aminosalicylate Prostaglandin G/H synthase 1 2000-01-01
(+)-Ketoprofen DEXKETOPROFEN marketed Nonsteroidal Anti-inflammatory Drug [EPC] Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 1994-01-01
MOFEZOLAC MOFEZOLAC marketed mofezolac Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1 1994-01-01
DEXIBUPROFEN DEXIBUPROFEN marketed dexibuprofen Prostaglandin G/H synthase 1 1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal Anti-inflammatory Drug [EPC] class)

  1. · 8 drugs in this class
  2. Pfizer · 2 drugs in this class
  3. Assiut University · 1 drug in this class
  4. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
  5. Centro Hospitalar Lisboa Ocidental · 1 drug in this class
  6. Dartmouth-Hitchcock Medical Center · 1 drug in this class
  7. Dr. Vishwanath Karad MIT World Peace University · 1 drug in this class
  8. Dr. Reddy's Laboratories Limited · 1 drug in this class
  9. Generic (originally Boots Group) · 1 drug in this class
  10. Boehringer Ingelheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Relafen — Competitive Intelligence Brief. https://druglandscape.com/ci/nabumetone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: